62 related articles for article (PubMed ID: 25503175)
1. Frequency and predisposing factors for interfractional rectal displacement requiring repeated precaution in prostate cancer patients treated with image-guided intensity-modulated radiation therapy.
Iwama K; Yamazaki H; Nishimura T; Oota Y; Aibe N; Nakamura S; Ikeno H; Yoshida K; Okabe H
Anticancer Res; 2014 Dec; 34(12):7373-8. PubMed ID: 25503175
[TBL] [Abstract][Full Text] [Related]
2. Interfractional Rectal Displacement Requiring Repeated Precaution Did Not Correlate to Biochemical Control and Rectal Toxicity in Patients with Prostate Cancer Treated with Image-guided Intensity-modulated Radiation Therapy.
Iwama K; Yamazaki H; Shimizu D; Suzuki G; Nakamura S; Sasaki N; Takeneka T; Okabe H; Nishikawa T; Yoshida K
Anticancer Res; 2017 Oct; 37(10):5755-5760. PubMed ID: 28982897
[TBL] [Abstract][Full Text] [Related]
3. Analysis of intrafractional organ motion for patients with prostate cancer using soft tissue matching image-guided intensity-modulated radiation therapy by helical tomotherapy.
Iwama K; Yamazaki H; Nishimura T; Oota Y; Aibe H; Nakamura S; Ikeno H; Yoshida K; Okabe H
Anticancer Res; 2013 Dec; 33(12):5675-9. PubMed ID: 24324116
[TBL] [Abstract][Full Text] [Related]
4. Exceptionally high incidence of grade 2-3 late rectal toxicity in patients with prostate cancer receiving hypofractionated (2.2 Gy) soft tissue-matched image-guided intensity-modulated radiotherapy.
Nishimura T; Yamazaki H; Aibe N; Nakamura S; Yoshida K; Okabe H
Anticancer Res; 2013 Dec; 33(12):5507-10. PubMed ID: 24324089
[TBL] [Abstract][Full Text] [Related]
5. Assessment of planning target volume margin for a small number of vertebral metastatic lesions using image-guided intensity-modulated radiation therapy by helical tomotherapy.
Nishimura T; Yamazaki H; Iwama K; Kotani T; Oota Y; Aibe H; Nakamura S; Ikeno H; Yoshida K; Isohashi F; Okabe H
Anticancer Res; 2013 Jun; 33(6):2453-6. PubMed ID: 23749895
[TBL] [Abstract][Full Text] [Related]
6. Analysis of intrafractional organ motion by megavoltage computed tomography in patients with lung cancer treated with image-guided stereotactic body radiotherapy using helical tomotherapy.
Aibe N; Yamazaki H; Nishimura T; Oota Y; Iwama K; Nakamura S; Ikeno H; Yoshida K; Okabe H; Yamada K
Anticancer Res; 2014 Dec; 34(12):7383-8. PubMed ID: 25503177
[TBL] [Abstract][Full Text] [Related]
7. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
Teh BS; Dong L; McGary JE; Mai WY; Grant W; Butler EB
Med Dosim; 2005; 30(1):25-30. PubMed ID: 15749008
[TBL] [Abstract][Full Text] [Related]
8. Late Rectal Toxicity from Image-guided Intensity Modulated Radiotherapy for Prostate Cancer.
Maki S; Itoh Y; Kubota S; Okada T; Nakahara R; Ito J; Kawamura M; Kamomae T; Naganawa S; Yoshino Y; Gotoh M; Ikeda M
Anticancer Res; 2016 Jun; 36(6):2967-73. PubMed ID: 27272812
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
[TBL] [Abstract][Full Text] [Related]
10. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
[TBL] [Abstract][Full Text] [Related]
12. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
14. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy.
Fiorino C; Di Muzio N; Broggi S; Cozzarini C; Maggiulli E; Alongi F; Valdagni R; Fazio F; Calandrino R
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):611-7. PubMed ID: 18374511
[TBL] [Abstract][Full Text] [Related]
15. Image-guided dose-escalated intensity-modulated radiation therapy for prostate cancer: treating to doses beyond 78 Gy.
Eade TN; Guo L; Forde E; Vaux K; Vass J; Hunt P; Kneebone A
BJU Int; 2012 Jun; 109(11):1655-60. PubMed ID: 22035373
[TBL] [Abstract][Full Text] [Related]
16. Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?
Sanguineti G; Cavey ML; Endres EJ; Brandon GG; Bayouth JE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):151-60. PubMed ID: 16198066
[TBL] [Abstract][Full Text] [Related]
17. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
18. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
19. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
20. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
